Last reviewed · How we verify
Latanoprost RATIOPHARM© latanoprost eyedrops
Latanoprost RATIOPHARM© latanoprost eyedrops is a Prostaglandin F2α analog Small molecule drug developed by University of Catanzaro. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: Latanoprost RATIOPHARM© eyedrops (RATIOPHARM GmbH - Ulm, Germany), authorization number:, 039468018/M.
Latanoprost is a prostaglandin F2α analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Latanoprost is a prostaglandin F2α analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Latanoprost RATIOPHARM© latanoprost eyedrops |
|---|---|
| Also known as | Latanoprost RATIOPHARM© eyedrops (RATIOPHARM GmbH - Ulm, Germany), authorization number:, 039468018/M |
| Sponsor | University of Catanzaro |
| Drug class | Prostaglandin F2α analog |
| Target | Prostaglandin F (FP) receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost acts as a selective agonist of the prostaglandin F (FP) receptor located on ciliary muscle bundle cells in the eye. By activating these receptors, it enhances drainage of aqueous humor through the unconventional uveoscleral pathway, reducing intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation (darkening)
- Conjunctival hyperemia (redness)
- Eyelash growth (hypertrichosis)
- Eye irritation or discomfort
- Periocular skin darkening
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Latanoprost RATIOPHARM© latanoprost eyedrops CI brief — competitive landscape report
- Latanoprost RATIOPHARM© latanoprost eyedrops updates RSS · CI watch RSS
- University of Catanzaro portfolio CI
Frequently asked questions about Latanoprost RATIOPHARM© latanoprost eyedrops
What is Latanoprost RATIOPHARM© latanoprost eyedrops?
How does Latanoprost RATIOPHARM© latanoprost eyedrops work?
What is Latanoprost RATIOPHARM© latanoprost eyedrops used for?
Who makes Latanoprost RATIOPHARM© latanoprost eyedrops?
Is Latanoprost RATIOPHARM© latanoprost eyedrops also known as anything else?
What drug class is Latanoprost RATIOPHARM© latanoprost eyedrops in?
What development phase is Latanoprost RATIOPHARM© latanoprost eyedrops in?
What are the side effects of Latanoprost RATIOPHARM© latanoprost eyedrops?
What does Latanoprost RATIOPHARM© latanoprost eyedrops target?
Related
- Drug class: All Prostaglandin F2α analog drugs
- Target: All drugs targeting Prostaglandin F (FP) receptor
- Manufacturer: University of Catanzaro — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Latanoprost RATIOPHARM© eyedrops (RATIOPHARM GmbH - Ulm, Germany), authorization number:, 039468018/M
- Compare: Latanoprost RATIOPHARM© latanoprost eyedrops vs similar drugs
- Pricing: Latanoprost RATIOPHARM© latanoprost eyedrops cost, discount & access